<?xml version="1.0" encoding="UTF-8"?>
<p id="Par43">To our knowledge, there is no prospective trial underway comparing HA-SIB-WBRT against HA-WBRT. We thus aim to test if there is a clinical benefit for the additional SIB in HA-WBRT. In preparation for this trial, we performed a planning study to test the feasibility of dosimetric targets set for HA-SIB-WBRT in 5 patients with different tumour numbers, volumes and locations as well as experimented with various treatment planning techniques [
 <xref ref-type="bibr" rid="CR17">17</xref>]. From this, we were then confident in our ability to proceed with our study.
</p>
